Pretreatment modified glasgow prognostic score predicts clinical outcomes after stereotactic body radiation therapy for early-stage non-small cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 92, Issue 3, 2015, Pages 619-626

  Kishi, Takahiro ^a   Matsuo, Yukinori ^a   Ueki, Nami ^a   Iizuka, Yusuke ^a   Nakamura, Akira ^a   Sakanaka, Katsuyuki ^a   Mizowaki, Takashi ^a   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; DISEASES; FACTOR ANALYSIS; MULTIVARIANT ANALYSIS; REGRESSION ANALYSIS;

COX PROPORTIONAL HAZARDS MODELS; DISTANT METASTASIS; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; NON SMALL CELL LUNG CANCER; PROGNOSTIC SIGNIFICANCE; RECURSIVE PARTITIONING ANALYSIS; STEREOTACTIC BODY RADIATION THERAPY;

RADIOTHERAPY;

C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROTEIN TYROSINE KINASE INHIBITOR; SERUM ALBUMIN;

AGED; ANALYSIS; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CHARLSON COMORBIDITY INDEX; DISTANT METASTASIS; EARLY CANCER; FEMALE; FLUOROSCOPY; FOLLOW UP; FOUR DIMENSIONAL COMPUTED TOMOGRAPHY; HUMAN; LIMIT OF DETECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MODIFIED GLASGOW PROGNOSTIC SCORE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RADIATION DOSE FRACTIONATION; RECURSIVE PARTITIONING ANALYSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; SURVIVAL TIME; AGE; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; EVALUATION STUDY; LUNG NEOPLASMS; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIOSURGERY; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

AGE FACTORS; AGED; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CAUSE OF DEATH; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOSURGERY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN; SEX FACTORS;

EID: 84930578580     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.02.018     Document Type: Article

References (38)

1. Surveillance, Epidemiology, and End Results Program, Statistical summaries, Cancer stat fact sheets, Cancer of the lung and bronchus; 2013. Available at: http://seer.cancer.gov/statfacts/html/lungb.html. Accessed August 21, 2014.
2. Y. Matsuo, K. Shibuya, and Y. Nagata Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer Int J Radiat Oncol Biol Phys 79 2011 1104 1111
3. J.R. Olsen, C.G. Robinson, and I. El Naqa Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer Int J Radiat Oncol Biol Phys 81 2011 e299 e303
4. P. Baumann, J. Nyman, and M. Hoyer Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy J Clin Oncol 27 2009 3290 3296
5. F.A. Mahmoud, and N.I. Rivera The role of C-reactive protein as a prognostic indicator in advanced cancer Curr Oncol Rep 4 2002 250 255
6. S. Wilop, M. Crysandt, and M. Bendel Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer Onkologie 31 2008 665 670
7. A. Koch, H. Fohlin, and S. Sörenson Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy J Thorac Oncol 4 2009 326 332
8. B. Gagnon, M. Abrahamowicz, and Y. Xiao Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer Br J Cancer 102 2010 1113 1122
9. O. Arrieta, R.M. Michel Ortega, and G. Villanueva-Rodriguez Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: A prospective study BMC Cancer 10 2010 50
10. L.M. Forrest, D.C. McMillan, and C.S. McArdle Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer Br J Cancer 90 2004 1704 1706
11. L.M. Forrest, D.C. McMillan, and C.S. McArdle A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer Br J Cancer 92 2005 1834 1836
12. D.J.F. Brown, R. Milroy, and T. Preston The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer J Clin Pathol 60 2007 705 708
13. E.Y. Leung, H.R. Scott, and D.C. McMillan Clinical utility of the pretreatment Glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer J Thorac Oncol 7 2012 655 662
14. L.H. Sobin, M.K. Gospodarowicz, and W. Christian TNM Classification of Malignant Tumours 7th Edition 2009 Wiley-Blackwell Hoboken (NJ)
15. M.E. Charlson, P. Pompei, and K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation J Chron Dis 40 1987 373 383
16. M.J. Proctor, P.G. Horgan, and D. Talwar Optimization of the systemic inflammation-based Glasgow prognostic score: A Glasgow Inflammation Outcome Study Cancer 119 2013 2325 2332
17. D.C. McMillan, K. Canna, and C.S. McArdle Systemic inflammatory response predicts survival following curative resection for colorectal cancer Br J Surg 90 2003 215 219
18. J.E. Crozier, R.F. McKee, and C.S. McArdle The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer Br J Cancer 94 2006 1833 1836
19. K. Takayama, Y. Nagata, and Y. Negoro Treatment planning of stereotactic radiotherapy for solitary lung tumor Int J Radiat Oncol Biol Phys 61 2005 1565 1571
20. Y. Kanda Investigation of the freely available easy-to-use software 'EZR' for medical statistics Bone Marrow Transplant 48 2013 452 458
21. D.C. Mcmillan The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer Cancer Treat Rev 39 2013 534 540
22. J.D. Bradley, I. El Naqa, and R.E. Drzymala Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: The pattern of failure is distant Int J Radiat Oncol Biol Phys 77 2010 1146 1150
23. K. Clarke, M. Taremi, and M. Dahele Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): Is FDG-PET a predictor of outcome? Radiother Oncol 104 2012 62 66
24. D.S. Lee, Y.S. Kim, and IeR. Yoo Long-term clinical experience of high-dose ablative lung radiotherapy: High pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome Lung Cancer 80 2013 172 178
25. Y. Satoh, A. Nambu, and H. Onishi Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy Eur J Radiol 81 2012 3530 3534
26. M.J. Burdick, K.L. Stephans, and C.A. Reddy Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy Int J Radiat Oncol Biol Phys 78 2010 1033 1039
27. D.B. Shultz, N. Trakul, and J.A. Abelson Imaging features associated with disease progression after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer Clin Lung Cancer 15 2014 294 301
28. D. Wu, H. Zhu, and H. Tang Clinical analysis of stereotactic body radiation therapy using extracranial Gamma Knife for patients with mainly bulky inoperable early stage non-small cell lung carcinoma Radiat Oncol 6 2011 84
29. D.C. McMillan, W.S. Watson, and P. O'Gorman Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss Nutr Cancer 39 2001 210 213
30. N. Songür, B. Kuru, and F. Kalkan Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer Tumori 90 2004 196 200
31. Y. Li, F.Y. Liu, and Z.H. Liu Effect of tacrolimus and cyclosporine A on suppression of albumin secretion induced by inflammatory cytokines in cultured human hepatocytes Inflamm Res 55 2006 216 220
32. M.D. Barber, K.C. Fearon, and M.J. Tisdale Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia Nutr Cancer 40 2001 118 124
33. I. Ikonomidis, F. Andreotti, and E. Economou Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin Circulation 100 1999 793 798
34. M.A. Albert, E. Danielson, and N. Rifai Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study JAMA 286 2001 64 70
35. J. Xu, Z. Yin, and W. Gao Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk Clin Lung Cancer 13 2012 44 51
36. V. Khurana, H.R. Bejjanki, and G. Caldito Statins reduce the risk of lung cancer in humans: A large case-control study of US veterans Chest 131 2007 1282 1288
37. S. Firat, M. Bousamra, and E. Gore Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 52 2002 1047 1057
38. N. Kopek, M. Paludan, and J. Petersen Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer Radiother Oncol 93 2009 402 407